person · Reporting owner
White William Richard
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Disc Medicine, Inc.IRON · Entity 2273 | Director | June 18, 2026 | June 23, 2026 |
| Yarrow Bioscience, Inc.YARW · Entity 6871 | Director | July 27, 2026 | July 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Disc Medicine, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.79 · Expires 2036-06-17 | Direct | 6,212 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 6,212 · Balance 6,212 F1: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.
Yarrow Bioscience, Inc.
Report date July 27, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.19 · Expires 2036-04-17 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-27 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer"). F2: Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the Reporting Person in the Merger in exchange for options to purchase shares of common stock of Yarrow held by the Reporting Person prior to the Merger. At the Effective Time, the Issuer assumed each such Yarrow option, whether vested or unvested, and converted it into an option to purchase shares of Issuer Common Stock on the same terms and conditions as were in effect immediately prior to the Effective Time. F3: This option represents a right to purchase 87,820 shares of Issuer Common Stock, one quarter of which will vest on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer").
F2: Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the Reporting Person in the Merger in exchange for options to purchase shares of common stock of Yarrow held by the Reporting Person prior to the Merger. At the Effective Time, the Issuer assumed each such Yarrow option, whether vested or unvested, and converted it into an option to purchase shares of Issuer Common Stock on the same terms and conditions as were in effect immediately prior to the Effective Time.
F3: This option represents a right to purchase 87,820 shares of Issuer Common Stock, one quarter of which will vest on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Akero Therapeutics, Inc.
Report date December 09, 2025 · Filed December 09, 2025
Section 16 reporting ended · disclosed 2025-12-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2025-12-09 · Disposition to issuer · Disposed 10,179 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2025-12-09 · Disposition to issuer · Disposed 47,573 · Balance 0 F2: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.23 · Expires 2034-12-16 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-09 · Disposition to issuer · Disposed 3,421 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.87 · Expires 2033-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-12-09 · Disposition to issuer · Disposed 5,032 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.95 · Expires 2032-12-09 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-12-09 · Disposition to issuer · Disposed 2,328 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-12-09 · Disposition to issuer · Disposed 4,739 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.35 · Expires 2030-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-12-09 · Disposition to issuer · Disposed 3,527 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.09 · Expires 2029-12-13 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-12-09 · Disposition to issuer · Disposed 18,964 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.23 · Expires 2034-12-16 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-12-09 · Disposition to issuer · Disposed 70,279 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.87 · Expires 2033-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-12-09 · Disposition to issuer · Disposed 116,833 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.08 · Expires 2033-11-09 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-12-09 · Disposition to issuer · Disposed 83,400 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.95 · Expires 2032-12-09 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2025-12-09 · Disposition to issuer · Disposed 84,051 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2025-12-09 · Disposition to issuer · Disposed 82,482 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2025-12-09 · Disposition to issuer · Disposed 29,074 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2025-12-09 · Disposition to issuer · Disposed 29,074 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2025-12-09 · Disposition to issuer · Disposed 29,073 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.35 · Expires 2030-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2025-12-09 · Disposition to issuer · Disposed 74,053 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.09 · Expires 2029-12-13 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2025-12-09 · Disposition to issuer · Disposed 24,745 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration").
F2: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU.
F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Ventyx Biosciences, Inc.
Report date March 04, 2026 · Filed March 04, 2026
Section 16 reporting ended · disclosed 2026-03-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.29 · Expires 2034-06-06 | Direct | 0 |
Reported balance
After 2026-03-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-04 · Disposition to issuer · Disposed 33,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F2: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2035-06-05 | Direct | 0 |
Reported balance
After 2026-03-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-04 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F2: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2034-01-21 | Direct | 0 |
Reported balance
After 2026-03-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-04 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F2: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.03 · Expires 2031-08-17 | Direct | 0 |
Reported balance
After 2026-03-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-04 · Disposition to issuer · Disposed 119,120 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F2: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.54 · Expires 2032-06-09 | Direct | 0 |
Reported balance
After 2026-03-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-04 · Disposition to issuer · Disposed 21,825 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F3: At the Effective Time, this option to purchase shares of the Issuer's common stock was fully vested and had an exercise price per share that was greater than the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.83 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2026-03-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-04 · Disposition to issuer · Disposed 15,937 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F3: At the Effective Time, this option to purchase shares of the Issuer's common stock was fully vested and had an exercise price per share that was greater than the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent.
F2: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes.
F3: At the Effective Time, this option to purchase shares of the Issuer's common stock was fully vested and had an exercise price per share that was greater than the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2024 Filed Jul 3, 2024 20:15 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionCommon Stock | 201 | $9.86 | $1,981.86 |
DisclosureSEC source: 0000950170-24-081524 · ownership.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on December 13, 2023. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:15 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $38.85 | $0.00 |
DisclosureSEC source: 0000950170-24-073676 · ownership.xml · derivative · entry 1 White William Richard · CIK 0001778739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-06-11 F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2025 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 18:09 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 2,831 | $22.64 | $64,093.84 |
DisclosureSEC source: 0000950170-24-073188 · ownership.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,799 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.500 to $22.760, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:32 UTC | Ventyx Biosciences, Inc. VTYX · Entity 62843 | GrantStock Option (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0001415889-24-015992 · form4-06072024_080654.xml · derivative · entry 1 White William Richard · CIK 0001778739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2034-06-06 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or, (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date the option was granted, in each case, subject to the reporting person continuing to be Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable vesting date. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:05 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 201 | $0.00 Strike: $9.86 | $0.00 |
DisclosureSEC source: 0000950170-24-069281 · ownership.xml · derivative · entry 7 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,010 Underlying: Common Stock · 201 shares Expires 2031-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on December 13, 2023. F6 · derivative.exercise_date: The shares underlying this option vest in 48 equal monthly installments following September 1, 2021, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:05 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,756 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0000950170-24-069281 · ownership.xml · derivative · entry 6 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,512 Underlying: Common Stock · 1,756 shares Expires 2030-11-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on December 13, 2023. F5 · derivative.exercise_date: The shares underlying this option vest in 16 equal quarterly installments following November 27, 2020, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:05 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 95 | $36.72 | $3,488.48 |
DisclosureSEC source: 0000950170-24-069281 · ownership.xml · nonDerivative · entry 5 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on December 13, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.655 to $36.77, inclusive. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:05 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 1,755 | $36.10 | $63,359.01 |
DisclosureSEC source: 0000950170-24-069281 · ownership.xml · nonDerivative · entry 4 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on December 13, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.575 to $35.565, inclusive. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:05 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 107 | $35.15 | $3,760.72 |
DisclosureSEC source: 0000950170-24-069281 · ownership.xml · nonDerivative · entry 3 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,850 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on December 13, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.54 to $35.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:05 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionCommon Stock | 201 | $9.86 | $1,981.86 |
DisclosureSEC source: 0000950170-24-069281 · ownership.xml · nonDerivative · entry 2 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on December 13, 2023. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:05 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionCommon Stock | 1,756 | $2.65 | $4,653.40 |
DisclosureSEC source: 0000950170-24-069281 · ownership.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on December 13, 2023. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:05 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 201 | $0.00 Strike: $9.86 | $0.00 |
DisclosureSEC source: 0000950170-24-052876 · ownership.xml · derivative · entry 4 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,211 Underlying: Common Stock · 201 shares Expires 2031-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on December 13, 2023. F4 · derivative.exercise_date: The shares underlying this option vest in 48 equal monthly installments following September 1, 2021, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:05 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 39 | $29.11 | $1,135.47 |
DisclosureSEC source: 0000950170-24-052876 · ownership.xml · nonDerivative · entry 3 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on December 13, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.79 to $29.682, inclusive. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:05 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 162 | $28.52 | $4,619.49 |
DisclosureSEC source: 0000950170-24-052876 · ownership.xml · nonDerivative · entry 2 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on December 13, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.79 to $28.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:05 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionCommon Stock | 201 | $9.86 | $1,981.86 |
DisclosureSEC source: 0000950170-24-052876 · ownership.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on December 13, 2023. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 22:27 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 804 | $0.00 Strike: $9.86 | $0.00 |
DisclosureSEC source: 0000950170-24-044538 · ownership.xml · derivative · entry 6 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,412 Underlying: Common Stock · 804 shares Expires 2031-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on December 13, 2023. F5 · derivative.exercise_date: The shares underlying this option vest in 48 equal monthly installments following September 1, 2021, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 22:27 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,756 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0000950170-24-044538 · ownership.xml · derivative · entry 5 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,268 Underlying: Common Stock · 1,756 shares Expires 2030-11-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on December 13, 2023. F4 · derivative.exercise_date: The shares underlying this option vest in 16 equal quarterly installments following November 27, 2020, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 22:27 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 78 | $32.18 | $2,510.01 |
DisclosureSEC source: 0000950170-24-044538 · ownership.xml · nonDerivative · entry 4 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on December 13, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.1247 to $32.3048, inclusive. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 22:27 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 2,482 | $31.79 | $78,896.82 |
DisclosureSEC source: 0000950170-24-044538 · ownership.xml · nonDerivative · entry 3 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on December 13, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.1178 to $32.1005, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 22:27 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionCommon Stock | 804 | $9.86 | $7,927.44 |
DisclosureSEC source: 0000950170-24-044538 · ownership.xml · nonDerivative · entry 2 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on December 13, 2023. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 22:27 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionCommon Stock | 1,756 | $2.65 | $4,653.40 |
DisclosureSEC source: 0000950170-24-044538 · ownership.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on December 13, 2023. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 16:44 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 724 | $28.33 | $20,510.92 |
DisclosureSEC source: 0000950170-24-032265 · ownership.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,630 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| January 21, 2024 Filed Jan 23, 2024 22:23 UTC | Ventyx Biosciences, Inc. VTYX · Entity 62843 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001209191-24-002099 · doc4.xml · derivative · entry 1 White William Richard · CIK 0001778739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-01-21 F1 · derivative.exercise_date: The shares subject to the option shall vest on the one-year anniversary of January 21, 2024, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan, the "Plan") through such date, provided that in the event of a Change in Control (as such term is defined in the Plan), one hundred percent (100%) of the then-unvested and outstanding shares subject to the Option will accelerate and fully vest, subject to the reporting person continuing to be an Outside Director (as the term is defined in the Company's Amended and Restated Outside Director Compensation Policy) through the date of the Change in Control. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 20:40 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 611 | $20.76 | $12,684.36 |
DisclosureSEC source: 0000950170-23-071246 · ownership.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,354 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 21:15 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0000950170-23-070396 · ownership.xml · derivative · entry 10 White William Richard · CIK 0001778739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2032-12-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 21:15 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,427 | $0.00 Strike: $9.86 | $0.00 |
DisclosureSEC source: 0000950170-23-070396 · ownership.xml · derivative · entry 9 White William Richard · CIK 0001778739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,216 Underlying: Common Stock · 5,427 shares Expires 2031-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares underlying this option vest in 48 equal monthly installments following September 1, 2021, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 21:15 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 21,084 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0000950170-23-070396 · ownership.xml · derivative · entry 8 White William Richard · CIK 0001778739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,024 Underlying: Common Stock · 21,084 shares Expires 2030-11-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares underlying this option vest in 16 equal quarterly installments following November 27, 2020, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 21:15 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 4,057 | $66.10 | $268,151.07 |
DisclosureSEC source: 0000950170-23-070396 · ownership.xml · nonDerivative · entry 7 White William Richard · CIK 0001778739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.00 to $66.3684, inclusive. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 21:15 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 16,263 | $65.26 | $1,061,341.27 |
DisclosureSEC source: 0000950170-23-070396 · ownership.xml · nonDerivative · entry 6 White William Richard · CIK 0001778739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,057 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.995, inclusive. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 21:15 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 1,091 | $63.73 | $69,532.05 |
DisclosureSEC source: 0000950170-23-070396 · ownership.xml · nonDerivative · entry 5 White William Richard · CIK 0001778739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,320 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.51 to $63.883, inclusive. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 21:15 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 12,100 | $59.44 | $719,214.32 |
DisclosureSEC source: 0000950170-23-070396 · ownership.xml · nonDerivative · entry 4 White William Richard · CIK 0001778739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,411 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.00 to $59.6974, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (4) to this Form 4. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 21:15 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionCommon Stock | 7,000 | $13.50 | $94,500.00 |
DisclosureSEC source: 0000950170-23-070396 · ownership.xml · nonDerivative · entry 3 White William Richard · CIK 0001778739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,511 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 21:15 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionCommon Stock | 5,427 | $9.86 | $53,510.22 |
DisclosureSEC source: 0000950170-23-070396 · ownership.xml · nonDerivative · entry 2 White William Richard · CIK 0001778739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,511 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 21:15 UTC | Disc Medicine, Inc. IRON · Entity 2273 | Exercise / conversionCommon Stock | 21,084 | $2.65 | $55,872.60 |
DisclosureSEC source: 0000950170-23-070396 · ownership.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 16:43 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 146,237 | $0.00 Strike: $19.87 | $0.00 |
DisclosureSEC source: 0000950170-23-069761 · ownership.xml · derivative · entry 2 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,237 Underlying: Common Stock · 146,237 shares Expires 2033-12-07 F2 · derivative.exercise_date: This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing from December 8, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 16:43 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantCommon Stock | 32,497 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-069761 · ownership.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,965 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in eight (8) equal semi-annual installments, commencing from December 8, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| November 09, 2023 Filed Nov 13, 2023 17:37 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 83,400 | $0.00 Strike: $14.08 | $0.00 |
DisclosureSEC source: 0000950170-23-063157 · ownership.xml · derivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,400 Underlying: Common Stock · 83,400 shares Expires 2033-11-08 F1 · derivative.exercise_date: 33% of the shares subject to this option shall vest and become exercisable on November 9, 2024, with the remainder vesting in 12 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| September 13, 2023 Filed Sep 25, 2023 20:31 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 632 | $50.34 | $31,814.88 |
DisclosureSEC source: 0000950170-23-049766 · ownership.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,468 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the reporting person. The sales reported on this Form 4 represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. Such sales were automatic and intended to qualify under Rule 10b5-1. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 17:20 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $7.01 | $0.00 |
DisclosureSEC source: 0000899243-23-016262 · doc4.xml · derivative · entry 3 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,329 Underlying: Common Stock · 17,500 shares Expires 2029-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options are vested and currently exercisable.. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 17:20 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 20,777 | $55.00 | $1,142,735.00 |
DisclosureSEC source: 0000899243-23-016262 · doc4.xml · nonDerivative · entry 2 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,100 Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 17:20 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 17,500 | $7.01 | $122,657.50 |
DisclosureSEC source: 0000899243-23-016262 · doc4.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 21:41 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 606 | $55.16 | $33,426.96 |
DisclosureSEC source: 0000899243-23-015674 · doc4.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,377 F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the reporting person. The sales reported on this Form 4 represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. Such sales were automatic and intended to qualify under Rule 10b5-1. Read SEC document |
| June 09, 2023 Filed Jun 9, 2023 22:16 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 7,136 | $0.00 Strike: $45.69 | $0.00 |
DisclosureSEC source: 0000899243-23-015264 · doc4.xml · derivative · entry 1 White William Richard · CIK 0001778739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,136 Underlying: Common Stock · 7,136 shares Expires 2033-06-08 F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2024 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:45 UTC | Ventyx Biosciences, Inc. VTYX · Entity 62843 | GrantStock Option (Right to Buy) · Derivative | 15,937 | $0.00 Strike: $34.83 | $0.00 |
DisclosureSEC source: 0001209191-23-036346 · doc4.xml · derivative · entry 1 White William Richard · CIK 0001778739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,937 Underlying: Common Stock · 15,937 shares Expires 2033-06-08 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or, (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date the option was granted, in each case, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable vesting date. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 16:25 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Tax withholdingCommon Stock | 641 | $43.47 | $27,864.27 |
DisclosureSEC source: 0000899243-23-008409 · doc4.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,983 F1 · kind: Represents shares required to be sold to satisfy tax withholding obligations of the Reporting Person related to the vesting of restricted stock units. Read SEC document |
| January 23, 2023 Filed Jan 24, 2023 23:33 UTC | Ventyx Biosciences, Inc. VTYX · Entity 62843 | Exercise / conversionStock Option (Right to Buy) · Derivative | 33,353 | $0.00 Strike: $6.03 | $0.00 |
DisclosureSEC source: 0001209191-23-004684 · doc4.xml · derivative · entry 5 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,120 Underlying: Common Stock · 33,353 shares Expires 2031-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Option granted under pursuant to the Issuer's 2019 Equity Incentive Plan, as amended (the "2019 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2019 Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 22, 2021. Read SEC document |
| January 23, 2023 Filed Jan 24, 2023 23:33 UTC | Ventyx Biosciences, Inc. VTYX · Entity 62843 | SaleCommon Stock | 7,027 | $35.91 | $252,336.06 |
DisclosureSEC source: 0001209191-23-004684 · doc4.xml · nonDerivative · entry 4 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the reporting person on September 22, 2022. F4 · price: The sales price reported is the weighted average sale price for 7,027 shares sold. These shares were sold in multiple transactions at prices ranging from $35.7054 to $36.48 by the reporting person. Full information regarding the number of shares sold at each separate price will be supplied upon request by Securities and Exchange Commission Staff, the Issuer or a security holder of the Issuer. Read SEC document |
| January 23, 2023 Filed Jan 24, 2023 23:33 UTC | Ventyx Biosciences, Inc. VTYX · Entity 62843 | SaleCommon Stock | 21,278 | $35.01 | $744,978.95 |
DisclosureSEC source: 0001209191-23-004684 · doc4.xml · nonDerivative · entry 3 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,027 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the reporting person on September 22, 2022. F3 · price: The sales price reported is the weighted average sale price for 21,278 shares sold. These shares were sold in multiple transactions at prices ranging from $34.705 to $35.7029 by the reporting person. Full information regarding the number of shares sold at each separate price will be supplied upon request by Securities and Exchange Commission Staff, the Issuer or a security holder of the Issuer. Read SEC document |
| January 23, 2023 Filed Jan 24, 2023 23:33 UTC | Ventyx Biosciences, Inc. VTYX · Entity 62843 | SaleCommon Stock | 5,048 | $34.33 | $173,276.64 |
DisclosureSEC source: 0001209191-23-004684 · doc4.xml · nonDerivative · entry 2 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,305 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the reporting person on September 22, 2022. F2 · price: The sales price reported is the weighted average sale price for 5,048 shares sold. These shares were sold in multiple transactions at prices ranging from $33.70 to $34.695 by the reporting person. Full information regarding the number of shares sold at each separate price will be supplied upon request by Securities and Exchange Commission Staff, the Issuer or a security holder of the Issuer. Read SEC document |
| January 23, 2023 Filed Jan 24, 2023 23:33 UTC | Ventyx Biosciences, Inc. VTYX · Entity 62843 | Exercise / conversionCommon Stock | 33,353 | $6.03 | $201,118.59 |
DisclosureSEC source: 0001209191-23-004684 · doc4.xml · nonDerivative · entry 1 White William Richard · CIK 0001778739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.